Get the Stockscreener App
1.42
5.19%
0.07
After Hours:
1.45
0.03
+2.11%
NanoViricides Inc stock is traded at $1.42, with a volume of 111.65K.
It is up +5.19% in the last 24 hours and up +10.94% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$1.35
Open:
$1.38
24h Volume:
111.65K
Relative Volume:
0.60
Market Cap:
$20.33M
Revenue:
-
Net Income/Loss:
$-8.29M
P/E Ratio:
-2.0286
EPS:
-0.7
Net Cash Flow:
$-6.47M
1W Performance:
+6.77%
1M Performance:
+10.94%
6M Performance:
-5.02%
1Y Performance:
+27.93%
1-Day Range:
$1.371
$1.42
1-Week Range:
$1.30
$1.42
52-Week Range:
$0.94
$3.59
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.42 | 20.33M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
Press Release Distribution & PR Platform - ACCESS Newswire
Nanostructured Drug Market Projected for Significant Expansion by 2032 -Nanoviricides Inc, Ablynx NV, Pfizer - newstrail.com
Small cap wrap: Gunnison Copper, Ocean Power Technologies, NanoViricides... - Proactive Investors
NanoViricides evaluating antiviral drug NV-387 for measles treatment - Proactive financial news
Measles Outbreak Expands Begging for a Drug to Treat the InfectionNanoViricides Declares it is Ready to Fight the Outbreak - Lelezard
NanoViricides, Inc. Appoints Irach Taraporewala as the New CEO and Nominates to Serve as a Member of the Board of Directors - marketscreener.com
Nanostructured Drug Market Detailed In New Research Report 2025 | Nanoviricides Inc., Ablynx NV, Pfizer - newstrail.com
NanoViricides unaffected by US tariff turmoil, says CFO - Proactive financial news
NNVC stock touches 52-week low at $1.02 amid market challenges - Investing.com Canada
NanoViricides unimpacted by tariffs; sees boost by changes at government agencies - Proactive Investors
NNVC stock touches 52-week low at $1.02 amid market challenges By Investing.com - Investing.com South Africa
NanoViricides highlights broad-spectrum antiviral strategy and progress with lead drug candidate - Proactive financial news
Virtu Financial LLC Acquires New Position in NanoViricides, Inc. (NYSE:NNVC) - Defense World
Small cap wrap: NanoViricides, G Mining Ventures, Nevis Brands... - Proactive Investors
NanoViricides eyes role in US bird flu fight as USDA unveils $100M initiative - Proactive Investors
NanoViricides Has Initiated Bio-analytical Studies as Part of IND-Enabling Safety and Toxicology Studies of Lead Candidate NV-HHV-101 - ACCESS Newswire
NanoViricides (NYSE:NNVC) Trading Up 1.7% – Time to Buy? - Defense World
Stock Update - Investorsobserver
AllPennyStocks.com News: Junior Biotech Bounces off $1; Chart Trying to Turn Bullish - ACCESS Newswire
Market movers: Delta, Kohl's, Asana, NanoViricides... - Proactive Investors
NanoViricides says business unaffected by US tariffs, highlights antiviral pipeline - Proactive financial news
Nanoviricides Co's Business Not Affected By Tariff Policies Of Us Government Or Corresponding Retaliatory Policies Of Other Governments - Marketscreener.com
NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company - Jonesboro Sun
Springing into action in time of need: NanoViricides, Inc. (NNVC.OB) - ACCESS Newswire
Unicycive Therapeutics Inc (NASDAQ:UNCY) stock: Is this a flash in the pan today? - US Post News
Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan - Lelezard
NanoViricides' NV-387 could provide a crucial missing weapon in the fight against US measles outbreak - Proactive financial news
Investornewsbreaks Nanoviricides (NYSE American: NNVC) Highlights NV-387 As Potential Measles Treatment Amid Outbreak - MENAFN.COM
NanoViricides Announces Pricing of $10.2 Million Registered Direct Offering - ACCESS Newswire
Mpox – a possible US$100mln+ opportunity - Proactive Investors USA
NanoViricides Successfully Completes Required Genetic Toxicology Testing of Lead Drug Candidate NV-HHV-101 - ACCESS Newswire
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am - ACCESS Newswire
NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Clinical Trials Application Ready - ACCESS Newswire
NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2020Has Sufficient Cash, Progress on New Coronavirus Drug Program and the Lead HerpeCide(TM) Drug Candidate IND Application - ACCESS Newswire
NanoViricides Receives Cash Infusion of $2.25 Million - ACCESS Newswire
NanoViricides Closes on $8.625 Million Underwritten Public Offering of Common Stock - ACCESS Newswire
NanoViricides Has Initiated Required Safety Pharmacology Assessment of Lead Drug Candidate towards IND - ACCESS Newswire
Small cap headlines: EnWave, NanoViricides, GoviEx, TNR Gold... - Proactive Investors UK
NanoViricides targets key milestones in 2025 with NV-387 advancing to Phase II trials - Proactive Investors USA
NanoViricides, Inc. Has Filed its Quarterly Report - Chronicle-Tribune
NanoViricides, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2024 - Marketscreener.com
NanoViricides Inc. (NNVC) reports earnings - Quartz
NanoViricides: Fiscal Q2 Earnings Snapshot - San Antonio Express-News
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):